Perlegen Sciences Inc., a Mountain View, Calif.-based developer of genetically-targeted medicines, has withdrawn registration of a proposed $115 million IPO. It had originally filed last April, with Lehman Brothers and Deutsche Bank Securities serving as co-lead underwriters. The company said that its withdrawal was “consistent with the public interest and the protection of investors.” Perlegen has raised around $256 million in total VC funding since its 2000 inception, from firms like Affymetrix, Pfizer, Maverick Capital, MPM Capital and CMEA Ventures. www.perlegen.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.